Apceth Starts First Phase I/II Clinical Study on Somatic Cell Therapy for Peripheral Arterial Occlusive Disease (pAOD)
B3C newswire, 08/24/2011
The Munich biotech company apceth started its first phase I/II clinical study on somatic cell therapy for advanced peripheral arterial occlusive disease (pAOD) after angioplasty. The aim is to investigate the tolerability and efficacy of somatic cell therapeutics developed by apceth for the treatment of pAOD. The study is designed as an open, randomised, monocentre study with two parallel patient groups and is being conducted in cooperation with the Isar–Medizinzentrum in Munich. The first patients have already been treated. A total of 30 patients are to be recruited into the study by March 2012. The initial results of the study are expected by mid 2012.